References
- World Health Organization. “Cardiovascular Diseases.” Accessed [1.09.2024]. Available from: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
- Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25 suppl 2): S49-73; DOI:10.1161/01.cir.0000437741.48606.98.
- Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95; DOI:10.1067/mcp.2001.113989. PMID: 11240971.
- Redberg RF, Vogel RA, Criqui MH, Herrington DM, Lima JAC, Roman MJ. Task force #3 -what is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis?. J Am Coll Cardiol. 2003;41(11):1886-98; DOI:10.1016/S0735-1097(03)00360-7.
- Strimbu K, Tavel JA. What are biomarkers?. Current Opinion in HIV and AIDS. 2010;5(6):463-6; DOI:10.1097/COH.0b013e32833ed177.
- Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G, Pyrgakis V, W.Cleman M. NTproBNP: An important biomarker in cardiac diseases. CTMC. 2013;13(2):82-94; DOI:10.2174/15680266 11313020002.
- Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem. 2005;40:1-36.
- McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004; DOI:10.1056/NEJMoa1409077.
- Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, Mc- Cullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-7; DOI:10.1056/NEJMoa020233.
- Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. The Am J Cardiol. 2005;95(8):948-54; DOI: 10.1016/j.amjcard.2004.12.032.
- Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330-7; DOI:10.1093/eurheartj/ehi631.
- Kim H, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015-9; DOI:10.1161/CIRCULATIONAHA.110.979500.
- Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943-50; DOI:10.1016/j.jacc.2007.02.037.
- Januzzi JL, Sakhuja R, O’Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315; DOI:10.1001/archinte.166.3.315.
- Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail. 2011;4(5):628-36; DOI:10.1161/CIRCHEARTFAILURE.111.962290.
- Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN; Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997-1003; DOI:10.1016/j. jacc.2008.04.069. PMID: 18786480.
- Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832(12):2442-50; DOI:10.1016/j. bbadis.2012.12.014.
- Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881-9; DOI:10.1016/j.jacc.2011.03.072.
- Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68(6):639-53; DOI:10.1016/j.jacc.2016.04.060.
- Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920-6; DOI:10.1161/01.cir.0000029801.86489.50.
- Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circulation Research. 1992;71(6):1501-7; DOI:10.1161/01.RES.71.6.1501.